ChengDa Pharmaceuticals Co. Ltd. (301201.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100005766

Price
23.70 CNY
Market cap
3.67 bn CNY
P/E (2025)
–
P/S (2025)
9.02
Dividend yield
0.84 %
Net margin
-2.93 %
Return on equity (ROE)
-0.57 %
Return on assets (ROA)
-0.51 %

ChengDa Pharmaceuticals Co. Ltd. financials

Fiscal year20242025
Revenue333.13 m CNY406.37 m CNY
Gross profit142.65 m CNY179.50 m CNY
Operating income-58.12 m CNY13.48 m CNY
EBIT-26.89 m CNY-10.98 m CNY
Net income-28.10 m CNY-11.93 m CNY
Diluted EPS – continuing operations-0.18 CNY-0.08 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ChengDa Pharmaceuticals Co. Ltd.

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, musculoskeletal system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.